A detailed history of Aton Ra Partners transactions in Edwards Lifesciences Corp stock. As of the latest transaction made, Aton Ra Partners holds 2,789 shares of EW stock, worth $210,234. This represents 0.42% of its overall portfolio holdings.

Number of Shares
2,789
Previous 3,101 10.06%
Holding current value
$210,234
Previous $214,000 0.93%
% of portfolio
0.42%
Previous 0.45%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 05, 2024

SELL
$61.71 - $77.76 $19,253 - $24,261
-312 Reduced 10.06%
2,789 $212,000
Q3 2023

Oct 25, 2023

BUY
$69.28 - $93.38 $623 - $840
9 Added 0.29%
3,101 $214,000
Q2 2023

Jul 18, 2023

SELL
$81.41 - $94.33 $48,846 - $56,598
-600 Reduced 16.25%
3,092 $291,000
Q1 2023

May 05, 2023

SELL
$74.26 - $84.51 $38,540 - $43,860
-519 Reduced 12.32%
3,692 $305,000
Q4 2022

Feb 02, 2023

SELL
$68.3 - $87.44 $65,021 - $83,242
-952 Reduced 18.44%
4,211 $314,000
Q3 2022

Nov 14, 2022

SELL
$82.37 - $107.29 $70,343 - $91,625
-854 Reduced 14.19%
5,163 $427,000
Q2 2022

Aug 15, 2022

SELL
$86.5 - $128.27 $787,842 - $1.17 Million
-9,108 Reduced 60.22%
6,017 $572,000
Q1 2022

May 16, 2022

SELL
$101.96 - $128.34 $777,037 - $978,079
-7,621 Reduced 33.5%
15,125 $1.78 Million
Q4 2021

Feb 14, 2022

BUY
$106.37 - $130.68 $838,727 - $1.03 Million
7,885 Added 53.06%
22,746 $2.95 Million
Q3 2021

Nov 15, 2021

BUY
$102.91 - $122.75 $230,930 - $275,451
2,244 Added 17.79%
14,861 $1.68 Million
Q2 2021

Aug 12, 2021

SELL
$83.84 - $104.76 $69,587 - $86,950
-830 Reduced 6.17%
12,617 $1.31 Million
Q1 2021

May 17, 2021

SELL
$78.68 - $90.67 $926,693 - $1.07 Million
-11,778 Reduced 46.69%
13,447 $1.13 Million
Q4 2020

Feb 19, 2021

BUY
$71.69 - $91.23 $1.81 Million - $2.3 Million
25,225 New
25,225 $2.3 Million

Others Institutions Holding EW

About Edwards Lifesciences Corp


  • Ticker EW
  • Exchange NYSE
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 618,259,968
  • Market Cap $46.6B
  • Description
  • Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair...
More about EW
Track This Portfolio

Track Aton Ra Partners Portfolio

Follow Aton Ra Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.